Anti Aggregation Peptides For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property | Value |
|---|---|
| Category | Disease-Modifying Therapy |
| Target | Protein Aggregation (Aβ, α-Syn, Tau, mHTT) |
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD |
| Stage | Preclinical to Phase I/II |
Anti-aggregation peptides are short amino acid sequences designed to prevent or reverse the misfolding and aggregation of pathogenic proteins in neurodegenerative diseases. These peptides typically work by binding to aggregation-prone regions of target proteins, blocking their self-assembly into toxic oligomers and fibrils.
Anti-aggregation peptides employ several strategies to combat protein aggregation:
Competitive Inhibition: Peptides containing sequences homologous to the aggregation-prone region compete with the full-length protein for self-assembly, forming non-toxic complexes instead.
β-Sheet Breakers: Peptides designed to bind β-sheet-rich aggregates and convert them to non-aggregating α-helical or random coil structures.
** chaperone Mimetics**: Peptides that mimic molecular chaperone activity, stabilizing the native conformation of proteins.
Oligomer Stabilization: Some peptides bind to early oligomers, stabilizing them into non-toxic forms (rather than blocking aggregation entirely).
Seeds Invalidation: Certain peptides can bind to aggregation seeds (nuclei) and prevent their ability to template further aggregation.
| Compound | Target | Condition | Phase | Status |
|---|---|---|---|---|
| ALZ-801 | Aβ aggregation | Alzheimer's Disease | Phase III | Ongoing |
| ACI-35 | Tau | Alzheimer's Disease | Phase I/II | Completed |
| GV1005 | Beta-amyloid | Alzheimer's Disease | Phase II | Completed |
| ABBV-0805 | Alpha-synuclein | Parkinson's Disease | Phase I | Completed |
The study of Anti Aggregation Peptides For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Solomon B. Immunotherapy and aggregation inhibitors for Alzheimer's disease. J Alzheimers Dis. 2020;75(2):423-430.
[2] Frydman-Marom A, et al. Targeting amyloid-β with cell-penetrating peptides. Angew Chem Int Ed Engl. 2011;50(18):4057-4061.
[3]lander R, et al. α-Synuclein aggregation and modulation of autophagy by peptide inhibitors. J Biol Chem. 2021;296:100720.
[4] Nagai Y, et al. Inhibition of polyglutamine fibril formation and neurotoxicity by a peptide corresponding to the expanded polyglutamine repeat. Hum Mol Genet. 2003;12(9):953-962.
[5] Wisén S, et al. Modulation of amyloid-β toxicity through targeting of central nervous system delivery. Adv Drug Deliv Rev. 2022;189:114539.
[6] Braun RJ, et al. Tau aggregation inhibitors for Alzheimer's disease: progress and challenges. J Med Chem. 2022;65(11):7563-7588.
[7] Scherzer-Okljik L, et al. Peptide-based inhibitors of protein aggregation in neurodegenerative diseases. Prog Mol Biol Transl Sci. 2021;183:155-193.
[8] Härd T, et al. Amyloid-β peptide antagonists: a structural perspective. ACS Chem Neurosci. 2020;11(3):363-375.